Potential for Optimization of Growth Hormone Treatment in Children with Growth Hormone Deficiency, Small for Gestational Age, and Turner Syndrome in Germany: Data from the PATRO® Children Study
Authors' conclusion
This study shows potential for improvement of GH treatment results in GHD, SGA, and TS patients in terms of early dose adjustment and younger age at the start of treatment. This is in accordance with important parameters used in prediction models.
Study context
- Population
- German growth hormone (GH)-treatment naïve children with growth hormone deficiency (GHD), short children born small for gestational age (SGA), and Turner syndrome (TS) starting GH treatment, PATRO Children database, 2007–2018
- Exposure
- Time periods of GH treatment start in GHD, SGA and TS
- Outcome
- Time trends in age, gender, GH dose, height standard deviation score (SDS), first-year growth response and Index of Responsiveness (IoR)
Methodological detailsGerman patients of the PATRO Children database, time-trend analysis, 3-year treatment-start groups 2007–2018
- German patients of the PATRO Children database
- Time-trend analysis, 3-year treatment-start groups 2007–2018
Main finding
As reported in the abstract
Chronological age at GH treatment start · 2007-2009 and 2016-2018
| Group | Value | 2016-2018 |
|---|---|---|
| GHD | 8.33 ± 3.19 | 8.04 ± 3.36 |
| SGA | 7.32 ± 2.52 | 6.67 ± 2.65 |
| TS | 8.65 ± 4.39 | 7.85 ± 3.38 |
Value
GHD8.33 ± 3.19
SGA7.32 ± 2.52
TS8.65 ± 4.39
2016-2018
GHD8.04 ± 3.36
SGA6.67 ± 2.65
TS7.85 ± 3.38
Observational data: associations, not effects.
Further findings
GH dose in first year of treatment
| Outcome | GHD | SGA | TS |
|---|---|---|---|
| Female patients | 32.3% | 43.6% | — not stated in the abstract |
| GH starting dose · treatment start | 0.026 mg/kg/day | 30.0 μg/kg/day | 33.7 μg/kg/day |
— not stated in the abstract
Female patients
- Females underrepresented vs males in GHD and SGA, no significant change over the 4 time periods
GH starting dose · treatment start
- SGA and TS started below the registered dose recommendation
GH dose in first year of treatment
- No significant change of GH dosing over time from 2007 to 2018
Index of Responsiveness (IoR)
- IoR comparable between time-groups for all 3 diagnoses
Original publication
Potential for Optimization of Growth Hormone Treatment in Children with Growth Hormone Deficiency, Small for Gestational Age, and Turner Syndrome in Germany: Data from the PATRO® Children Study. Horm Res Paediatr. Published 25 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →